

Swiss-based OncoCoin to launch crypto token AMRIT for patients in India

11 November 2021 | News

The company plans to launch the neurology app by the end of this year covering Alzheimer's disease, Parkinson Disease



Swiss-based OncoCoin, a fully-owned subsidiary of Innoplexus, a leading international Artificial Intelligence (AI) and blockchain-based drug discovery and development company, will launch 'AMRIT', a decentralised and GDPR compliant Real World Data (RWD) exchange to fuel AI for patient's health and longevity.

'AMRIT' ecosystem will create a level playing field for the 1.3 billion Indians by putting them at the heart of the healthcare solution. Over 3,50,000 users benefit globally by using this platform.

Cancer research can be drastically accelerated using diverse Real World patient data. This data has become an invaluable asset for companies doing research in Life Sciences, but sharing of the data doesn't provide any benefits to the patients.

Built on top of a blockchain, the 'Cancer Twin', feature in the CURIA App enables users to identify other users with similar disease types to communicate anonymously with each other.

Dr Gunjan Bhardwaj, CEO, Innoplexus and Founder/Chairman of the Board, OncoCoin, said, "The AMRIT ecosystem is democratising the process of cancer research by offering a base of 3.5 lakh users globally registered on the mobile app CURIA. Through the app, the pharma companies seeking to conduct clinical trials can connect with the patients for their participation and incentivise them for sharing their real-world data with the utility token 'AMRIT.'

The company also plans to launch a neurology app by the end of this year covering Alzheimer's disease, Parkinson Disease among others.